Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Miljø, patogener og værtsinteraktioner ved melioidose (DeEPH)

17. september 2026 opdateret af: University of Oxford

Afkodning af triaden: samspillet mellem miljø, patogen og vært ved melioidose (DeEPH)

This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.

The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.

For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.

In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.

This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:

  • Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
  • Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
  • Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).

In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.

Participant Recruitment and Follow-up

Hospital cohort:

Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).

Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.

Healthy controls:

Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.

Community cohort:

To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.

Community cohort:

To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

2400

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Kamolchanok Claire Chewapreecha, PhD
  • Telefonnummer: 662 203 6333
  • E-mail: claire@tropmedres.ac

Studiesteder

      • Siem Reap, Cambodja
        • Ikke rekrutterer endnu
        • Cambodia-Oxford Medical Research Unit (COMRU)
        • Kontakt:
      • Vientiane, Laos
        • Ikke rekrutterer endnu
        • Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
        • Kontakt:
      • Ubon Ratchathani, Thailand
        • Rekruttering
        • Sunpasitthiprosong Hospital
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

20 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Melioidosis patients:

Patients confirmed to have melioidosis.

Healthy controls:

For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence.

Sandbox Village residents:

All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.

Beskrivelse

Inclusion criteria for melioidosis patients:

  • Age ≥20 years
  • Positive for Burkholderia pseudomallei from any clinical samples
  • Resident of the study area for at least two years, including the follow-up period
  • Willing to participate and give informed consent.

Inclusion criteria for healthy controls:

  • Age ≥20 years
  • Currently healthy as judged by study doctor
  • Resident of the study area for at least two years, including the follow-up period
  • Willing to participate and give informed consent.

Inclusion criteria for sandbox residents:

  • Age ≥20 years
  • Resident of the study area for at least two years, including the follow-up period
  • Willing to participate and give informed consent.

Exclusion criteria for melioidosis patients:

  • Current tuberculosis (TB) or TB treatment within the past six months
  • Documented HIV infection or use of immunosuppressive therapy in the past 12 months

Exclusion criteria for healthy controls:

  • History of melioidosis
  • Significant acute illness
  • Current fever or soft tissue infection

Exclusion criteria for sandbox residents

-N/A

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
Melioidosis patients

Patients confirmed to have melioidosis

Healthy controls

Healthy controls will be enrolled for each confirmed melioidosis case. A healthy control is defined as an individual with no current fever, no evidence of soft tissue infection, and no prior history of melioidosis. Controls will be recruited within approximately two weeks of case identification and will be matched to cases by age (±5 years), sex, and village of residence.

Sandbox village cohort

All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Udvikling af melioidose efter eksponering, vurderet blandt melioidose-tilfælde
Tidsramme: 365 dage
365 dage
Udvikling af melioidose efter eksponering, vurderet blandt raske kontroller
Tidsramme: 365 dage
365 dage
Udvikling af melioidose efter eksponering, vurderet blandt beboere i Sandbox Village
Tidsramme: 3,5 år
3,5 år
Dødelighed i den akute fase af infektion blandt personer med melioidose (melioidose-tilfælde).
Tidsramme: 365 dage
365 dage
Antallet af genindlæggelser på hospital efter udskrivelse blandt personer med melioidose (melioidose-tilfælde).
Tidsramme: 365 dage
365 dage

Sekundære resultatmål

Resultatmål
Tidsramme
Ændringer i sygdomsudvikling efter eksponering forbundet med interaktioner mellem miljømæssige ændringer.
Tidsramme: 3,5 år
3,5 år
Ændringer i dødeligheden under den akutte fase af infektion efter eksponering forbundet med interaktioner mellem miljøændringer.
Tidsramme: 365 dage
365 dage
Ændringer i genindlæggelse på hospital efter bedring forbundet med samspil mellem miljøtilpasninger.
Tidsramme: 365 dage
365 dage
Ændringer i sygdomsudviklingen efter eksponering forbundet med interaktioner mellem kliniske behandlingsfaktorer.
Tidsramme: 365 dage
365 dage
Ændringer i dødeligheden under infektionens akutte fase efter eksponering forbundet med interaktioner mellem kliniske behandlingsfaktorer.
Tidsramme: 365 dage
365 dage
Ændringer i genindlæggelse på hospital efter bedring forbundet med interaktioner mellem kliniske behandlingsfaktorer.
Tidsramme: 365 dage
365 dage
Ændringer i sygdomsudviklingen efter eksponering forbundet med interaktioner, der involverer genetisk modtagelighed.
Tidsramme: 365 dage
365 dage
Ændringer i dødeligheden under infektionens akutte fase efter eksponering forbundet med interaktioner, der involverer genetisk modtagelighed.
Tidsramme: 365 dage
365 dage
Ændringer i genindlæggelse på hospital efter bedring forbundet med interaktioner, der involverer genetisk modtagelighed.
Tidsramme: 365 dage
365 dage

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Kamolchanok Claire Chewapreecha, PhD, Mahidol Oxford Tropical Research Unit

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

19. august 2026

Primær færdiggørelse (Anslået)

1. december 2034

Studieafslutning (Anslået)

1. december 2034

Datoer for studieregistrering

Først indsendt

7. januar 2026

Først indsendt, der opfyldte QC-kriterier

7. januar 2026

Først opslået (Faktiske)

16. januar 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • MEL25001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The study outputs, including genomic and transcriptomic data and associated metadata, will be valuable for future research. In compliance with the Wellcome Trust's open data policies and to encourage reproducibility, data will be deposited in two repositories:

Human genomic and transcriptomic data: European Genome-Phenome Archive (EGA), under managed access

Bacterial genomic data: European Nucleotide Archive (ENA), open access

Pseudonymised metadata, including participant demographics and microbiological findings, will be shared with qualified researchers in accordance with the General Data Protection Regulation (GDPR). No personally identifiable information will be shared, and participants will not be identifiable from any released data.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .